Skip to main content

Valneva SE

corporate_fare Company Profile

Valneva SE

VALN·NASDAQ·Life Sciences·CIK 0001836564

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. The company focuses on providing first-, best-, or only-in-class vaccine solutions. Valneva currently markets three proprietary travel vaccines. Its clinical portfolio includes vaccine candidates designed to provide preventative solutions for diseases with high unmet need. The company's pipeline includes VLA15, a Lyme disease vaccine candidate in advanced clinical development, which is being developed in partnership with Pfizer. VLA15 is a Phase 3 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease, and is the only vaccine candidate against Lyme disease currently undergoing late-stage clinical trials. Pfizer and Valneva are executing the Phase 3 field efficacy trial for VLA15, called VALOR (Vaccine Against Lyme for Outdoor Recreationists). Vaccinations were completed in July 2025, and participants were monitored for Lyme disease cases until the end of 2025. VLA15 targets the six most prevalent serotypes of Borrelia in the Northern Hemisphere. Approximately 476,000 people are diagnosed with Lyme disease each year in the United States, and at least 132,000 cases occur annually in Europe. Valneva's pipeline also includes the world's most clinically advanced tetravalent Shigella vaccine candidate, under development in collaboration with LimmaTech Biologics AG. Additionally, VLA1553 is a single-dose, live-attenuated vaccine against chikungunya, currently marketed outside the United States under the brand name IXCHIQ. This product continues to be evaluated in ongoing Phase 3/4 clinical trials, including post-marketing studies.

Valneva SE (NASDAQ:VALN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for VALN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for VALN spans 6-K, 424B3, F-3, SCHEDULE 13D/A.

Recent high-impact activity:

  • Valneva 6-K Packs Shigella Phase 2 Win and 94% Five-Year Chikungunya Persistence
  • Valneva's Shigella Vaccine Hits Phase 2 Endpoints in Infant and Adult Trials
  • UK Revokes Marketing Authorization for Valneva's Chikungunya Vaccine
  • EMA Validates Valneva's Lyme Vaccine MAA; Phase 3 Shows >70% Efficacy
  • Valneva H1 2026: Net Loss Triples to €63.3M on IXCHIQ Charges; Guidance Reaffirmed

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€174.66M EUR
Net Income
-€115.19M EUR
Diluted EPS
-€0.68 EUR
Op. Cash Flow
-€52.89M EUR
Free Cash Flow
-€57.31M EUR
Gross Profit
€67.52M EUR
Operating Income
-€82.06M EUR
Cash & Equivalents
€109.65M EUR
Total Debt
€161.26M EUR
Debt / Equity
1.52×
Net Margin
-66.0%
Shares Outstanding
173.54M sh
Source: 20-F · filed 2026-03-17 · accession 0001628280-26-018808

Short Interest & Short Volume

2.05 days to cover

FINRA reported short interest of 47,986 shares in VALN as of the October 30, 2026 settlement, a 75.0% decrease from the prior period — about 2.0 days to cover at its recent average daily volume. On November 19, 2026, 15.7% of VALN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)47,986 shares as of October 30, 2026
Change vs prior period▼ 75.0%
Days to cover2.05 at avg daily volume of 23,384
Daily short volume (FINRA facilities)15.7% of 440 shares on November 19, 2026
5-day average short volume13.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for VALN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-04.

1 shelf registration

Resale Registration Filed · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

VALN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with V →
$5.17 -3.73% today
52-week range · as of 2026-11-13 $4.75 – $12.18
Market cap
$511.07M
Volume
15K (0.9× avg)
3-mo avg 16.4K
Live data · 2026-11-20 20:51 UTC · Market open

show_chartPrice Chart

Loading chart...

feed VALN - Latest Insights

VALN
Nov 13, 2026, 10:09 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.84
Real-time Price: $5.17 info
Change: -$0.675 (-12%) info
Market Cap: $511.074M info
VALN
Nov 09, 2026, 10:37 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $5.79
Real-time Price: $5.17 info
Change: -$0.625 (-11%) info
Market Cap: $511.074M info
VALN
Oct 07, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $5.17 info
Change: -$0.445 (-8%) info
Market Cap: $511.074M info
VALN
Aug 14, 2026, 11:27 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.01
Real-time Price: $5.17 info
Change: -$1.84 (-26%) info
Market Cap: $511.074M info
VALN
Aug 13, 2026, 10:27 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.45
Real-time Price: $5.17 info
Change: -$0.285 (-5%) info
Market Cap: $511.074M info
VALN
Aug 13, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.55
Real-time Price: $5.17 info
Change: -$0.385 (-7%) info
Market Cap: $511.074M info
VALN
Jun 25, 2026, 11:57 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.13
Real-time Price: $5.17 info
Change: +$0.035 (+0.68%) info
Market Cap: $511.074M info
VALN
Jun 16, 2026, 4:48 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $5.36
Real-time Price: $5.17 info
Change: -$0.195 (-4%) info
Market Cap: $511.074M info
VALN
Jun 04, 2026, 5:05 PM EDT
Filing Type: F-3
Importance Score:
7
Price at Filing: $5.67
Real-time Price: $5.17 info
Change: -$0.505 (-9%) info
Market Cap: $511.074M info
VALN
May 13, 2026, 4:49 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $5.17 info
Change: -$0.705 (-12%) info
Market Cap: $511.074M info
VALN
May 13, 2026, 1:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $6.25
Real-time Price: $5.17 info
Change: -$1.09 (-17%) info
Market Cap: $511.074M info
VALN
May 12, 2026, 5:09 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.00
Real-time Price: $5.17 info
Change: -$0.835 (-14%) info
Market Cap: $511.074M info
VALN
Apr 30, 2026, 5:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.38
Real-time Price: $5.17 info
Change: -$0.215 (-4%) info
Market Cap: $511.074M info
VALN
Apr 30, 2026, 1:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.33
Real-time Price: $5.17 info
Change: -$0.165 (-3%) info
Market Cap: $511.074M info
VALN
Mar 23, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.51
Real-time Price: $5.17 info
Change: -$1.34 (-21%) info
Market Cap: $511.074M info
VALN
Mar 18, 2026, 11:21 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $5.17 info
Change: -$5.84 (-53%) info
Market Cap: $511.074M info
VALN
Mar 17, 2026, 4:33 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $11.01
Real-time Price: $5.17 info
Change: -$5.85 (-53%) info
Market Cap: $511.074M info
VALN
Feb 19, 2026, 6:19 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $10.80
Real-time Price: $5.17 info
Change: -$5.64 (-52%) info
Market Cap: $511.074M info
VALN
Feb 13, 2026, 11:51 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $10.20
Real-time Price: $5.17 info
Change: -$5.04 (-49%) info
Market Cap: $511.074M info
VALN
Feb 03, 2026, 9:17 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.15
Real-time Price: $5.17 info
Change: -$3.99 (-44%) info
Market Cap: $511.074M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets